Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tharimmune, Inc. (NASDAQ: THAR) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission, including its Current Reports on Form 8-K, proxy materials, and other registration documents. These filings provide primary-source detail on Tharimmune’s clinical-stage biotechnology programs and its Canton Coin-focused digital asset treasury strategy.
Recent Form 8-K filings describe material definitive agreements such as securities purchase agreements for private placements involving common stock and pre-funded warrants, as well as an at-the-market sales agreement for common stock. They also outline the structure and intended use of proceeds from offerings designed to support both Tharimmune’s historical biotech operations and the establishment of a Canton Coin treasury and related Canton Network participation.
Other 8-Ks and proxy materials detail corporate governance and compensation matters, including amendments to the certificate of incorporation to increase authorized common stock, changes to the omnibus equity incentive plan, and the appointment of key executives such as the Chief Executive Officer, President, and Chief Financial Officer. These documents specify employment agreement terms, severance provisions, and equity award structures for senior leadership associated with the company’s biotechnology and digital asset initiatives.
Investors can also use this page to access risk factor discussions related to Tharimmune’s Canton Coin strategy, as described in its filings, including risks tied to digital asset volatility, regulatory uncertainty, and liquidity considerations. Proxy statements provide additional context on share authorization proposals and future offering authorizations under Nasdaq rules.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, capital structure changes, and leadership updates, helping readers quickly interpret complex legal and financial language. From here, you can review Tharimmune’s 8-Ks, registration statements, and proxy materials, and use the platform’s tools to track insider-related disclosures and ongoing financing arrangements as they appear in the EDGAR feed.
Vincent S. LoPriore filed an Initial Statement of Beneficial Ownership (Form 3) reporting his positions with Tharimmune, Inc. (THAR). He is listed as a Director, 10% owner and Executive Chairman. The filing shows 732,424 shares of common stock held indirectly through Gravitas Capital LP and several derivative instruments: a 100,000 stock option (exercise price $1.33, 50,000 vested at grant, remainder vests 08/04/2026), 337,838 Series A warrants ($1.29), 168,918 Series B warrants ($3.00) and 443,806 Common Stock Purchase Warrants ($2.03). The reporting person disclaims beneficial ownership except to extent of pecuniary interest.
Gary S. Stetz, a director of Tharimmune, Inc. (THAR), filed an initial Form 3 reporting beneficial ownership arising from an event on 04/28/2025. He directly owns 101,351 shares of common stock. He holds a stock option for 50,000 shares exercisable (with 25,000 shares vested on grant and 25,000 vesting on 08/04/2026) at an exercise price of $1.33. He also holds Series A warrants for 101,351 shares (strike $1.29, expiring 12/13/2030) and Series B warrants for 50,675 shares (strike $3.00, expiring 12/13/2030). The form is signed on 08/20/2025.
Tharimmune, Inc. is a clinical-stage biotech focused on immunology and inflammation programs, including TH104 (buccal film) and oral infliximab programs licensed from Avior and Intract. The company received FDA IND approval for TH104 in February 2023 and reported positive FDA feedback in March 2025 on a Pre-IND request for a prophylactic high-potency opioid indication (PrHPO), where the FDA indicated a 505(b)(2) NDA pathway is feasible with additional nonclinical in vitro toxicology but no new clinical trials expected to define the prophylactic dosing window.
Financially, Tharimmune had $2.24 million in cash and